Induction of neural oscillations by flickering light is a well established method used for diagnostic of various neural diseases. Recent studies in mice have shown promising results indicating that induction of gamma oscillation at 40 Hz leads to a reduction in amyloid-β and tau in mice models of Alzheimer's disease. This study will use flickering light to induce 40 Hz gamma oscillation as the previously mentioned studies. In the study subject will be exposed to invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) for 1 hour each day. The sham setting is a high quality sham intervention as subjects will be blinded to the setting, both appears as white light. As this is the first trial, the focus will be on 1) safety of the intervention 2) feasibility of the proposed intervention time and method 3) indication of efficacy. In stage 1 of the trial 4 age-matched subjects with no Alzheimer's disease will be recruited and be exposed for 1 week. In stage 2 10 patients with Alzheimer's disease will be recruited and exposed for 6 consecutive weeks.
Induction of neural oscillations by flickering light is a well established method used for diagnostic of various neural diseases (5,6). Recent studies in mice have shown promising results indicating that induction of gamma oscillation at 40 Hz leads to a reduction in amyloid-β an tau in mice models of Alzheimer's disease (1-4). This study will use flickering light to induce 40 Hz gamma oscillation as the previously mentioned studies. This study will utilize a novel way of masking the light by alternating the spectral composition of a white light, rendering the flicker invisible to the conscience perception while still entraining 40 Hz oscillations in the brain. In the study subject will be exposed to invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) for 1 hour each day. The sham setting is a high quality sham intervention as subjects will be blinded to the setting, both appears as white light. As this is the first trial, the focus will be on 1) safety of the intervention 2) feasibility of the proposed intervention time and method 3) indication of efficacy. In stage 1 of the trial 4 age-matched subjects with no Alzheimer's disease will be recruited and be exposed for 1 week. In stage 2 10 patients with Alzheimer's disease will be recruited and exposed for 6 consecutive weeks. Following the 6 weeks of intervention the subject will have 6 weeks of no intevention and assesed agian.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
16
Exposure for 1 hour á day for consecutive days.
Exposure for 1 hour á day for consecutive days.
Zealand University DK34197393
Roskilde, Region Sjælland, Denmark
Stage I: Feasibility / Compliance assesment
• The compliance of the LTS intervention will be measured by the amount of time (in minutes) of device use per day.
Time frame: After 1 week of intervention
Stage I: Usability Assessment:
• Usability report on use of device during intervention in the subject's home based on device speciffic questionnaire / structured interviews
Time frame: After 1 week of intervention
Stage I: Safety Assessment. Evaluation of Adverse Events related to the LTS intervention.
• Safety assessment will be done by collection of all types of adverse events and categorization into severity and relationship to LTS treatment.
Time frame: After 1 week of intervention
Stage II: Feasibility / Compliance assesment
• The compliance of the LTS intervention will be measured by the amount of time (in minutes) of device use per day.
Time frame: After 6 weeks of intervention and subsequent 6 weeks of no intervention
Stage II: Safety Assessment. Evaluation of Adverse Events related to the LTS intervention.
• Device- and procedure-related adverse events (DR/PR-AEs) including serious AEs (SAEs) occurring at any time during the trial
Time frame: After 6 weeks of intervention and subsequent 6 weeks of no intervention
Stage II: Induction of gamma ocsillations
• The effect of the LTS intervention will be measured by the amount of 40 Hz SSVEP response during treatment
Time frame: Changes from baseline to 6 and 12 weeks
Stage II: Connectivity meassures in resting-state functional MRI
• rs-fMRI Connectivity: Change from baseline in correlations between cortical regions at 6 weeks
Time frame: Changes from baseline to 6 and 12 weeks
Stage II: Connectivity meassures in EEG
• EEG Connectivity: Change from baseline in correlations between cortical regions at 6 weeks
Time frame: Changes from baseline to 6 and 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.